Core-Binding Factor Subunit Beta (CBFB) is a master regulator of hematopoiesis and a critical node in transcription factor-driven oncogenesis. Primarily known for its heterodimerization with RUNX family proteins (RUNX1, RUNX2, RUNX3), CBFB stabilizes the RUNX complex to enhance DNA binding affinity. Genetic alterations in CBFB, particularly the inv(16)(p13q22) chromosomal translocation yielding the CBFB-MYH11 fusion protein, are hallmark drivers of Acute Myeloid Leukemia (AML) subtype M4eo. Disrupting the CBFB-RUNX1 interaction or selectively targeting the CBFB-MYH11 fusion represents a highly promising therapeutic strategy for leukemia and select solid tumors.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CBFB drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CBFB Recombinant Protein (Full-length & truncated domains) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CBFB Products |
| Gene Delivery | CBFB Promise-ORF / Lentivirus Full-length ORF for stable reporter cell line generation. |
View CBFB Products |
| Benchmark Ab | Anti-CBFB Recombinant Antibody Sequence-verified positive control for Western Blot, IP, and ChIP assays. |
View CBFB Products |
| Validator | CBFB siRNA Set Validated sequence pool for target knockdown and specificity verification. |
View CBFB Products |
| Related Target A | RUNX1 Primary heterodimerization partner; required for CBFB-RUNX1 protein-protein interaction (PPI) disruption assays. |
View RUNX1 Products |
| Related Target B | RUNX2 Essential partner in osteoblast differentiation; utilized for cross-family selectivity screening. |
View RUNX2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening complexity | Highly stable, monomeric CBFB and RUNX1 partner proteins available with verified theoretical MW and high purity (>95%) for robust SPR/BLI assays. |
| Specificity over homolog complexes | Complete panel of RUNX1, RUNX2, and RUNX3 proteins to perform rigorous off-target counter-screening. |
| Lack of Controls | Sequence-defined, high-affinity clinical benchmark antibodies and validated positive controls included in the catalog. |
| False Positives | Pre-designed, sequence-verified siRNA sets included to confirm target-specific cell phenotypes post-treatment. |
Live CBFB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CBFB is undergoing a transition from basic transcription factor biology to targeted clinical translation. Because CBFB is an intracellular protein lacking intrinsic enzymatic activity, drug discovery efforts focus heavily on small molecule inhibitors of protein-protein interactions (PPIs) and targeted protein degraders (PROTACs). The clinical development pipeline is dominated by therapies targeting the CBFB-MYH11 fusion in AML, alongside emerging indications in breast cancer where CBFB acts as a context-dependent tumor suppressor or oncogenic cofactor.
The race for CBFB therapeutics is intensifying, with major players shifting focus from traditional systemic chemotherapies to highly targeted transcription factor inhibitors. As first-generation small molecules targeting the CBFB-RUNX1 interface advance through lead optimization, the next wave of R&D is targeting the selective degradation of the CBFB-MYH11 fusion protein while sparing wild-type CBFB to avoid hematological toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Consortia, Biotech Startups | Acute Myeloid Leukemia (AML) | Disruption assays (Need sequence-verified, highly stable CBFB and RUNX1 proteins) |
| PROTAC / Degrader | Targeted Protein Degradation Pioneers | Inv(16) AML, Solid Tumors | Ternary complex validation (Need high-purity CBFB recombinant proteins) |
| Lentiviral / Gene Therapy | Gene Therapy Developers | Refractory Leukemias | Stable cell line construction (Need high-titer Lentivirus Premade Particles) |